Enforcement Report - Week of May 1, 2024
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry
FDA clears Otsuka, Click's prescription app for depression
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
The European Commission (EC) has approved Otsuka Pharmaceutical Europe and H Lundbeck’s Abilify Maintena 720mg/960mg (aripiprazole) for the maintenance treatment of schizophrenia.
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease
Otsuka and Sumitomo Revise License Agreement
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors
Japan headquartered Otsuka Pharmaceutical Co. has concluded an investment contract of $30 million with AN Venture Partners (ANV), a global capital fund aiming to create global biotech companies that leverage science from Japan.
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation